An FDA-approved treatment for acute otitis externa, commonly known as swimmer’s ear
XTORO® is a quinolone antimicrobial indicated for the treatment of acute otitis externa caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients 1 year of age and older.
See Full Prescribing Information
To learn more, visit XTORO.us
About XTORO
XTORO® is a prescription antibacterial ear drop for the treatment of acute otitis externa, commonly known as swimmer’s ear. Acute otitis externa is an infection of the external ear canal that can cause ear pain, tenderness, swelling, redness, and discharge.
XTORO contains finafloxacin, a fluoroquinolone antimicrobial. In clinical studies, XTORO was evaluated in patients with acute otitis externa and demonstrated clinical and microbiological outcomes superior to vehicle, as well as a shorter median time to cessation of ear pain. The full prescribing information reports median time to cessation of ear pain of 3.5 days for XTORO-treated pathogen-positive patients compared with 6.8 days for vehicle.
XTORO is for topical otic use only.
See Full Prescribing Information
INDICATION
XTORO® is a quinolone antimicrobial indicated for the treatment of acute otitis externa caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.
IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
As with other antibacterial preparations, prolonged use of XTORO may lead to overgrowth of nonsusceptible organisms, including yeast and fungi. If this occurs, discontinue use and institute alternative therapy.
Allergic reactions to XTORO may occur in patients with a history of hypersensitivity to finafloxacin, to other quinolones, or to any of the components in this medication. If this occurs, discontinue use and institute alternative therapy.
Adverse Reactions
In clinical trials, the most frequently reported adverse reactions in patients exposed to XTORO occurring at an incidence of 1% included ear pruritus and nausea.
Use in Specific Populations
The safety and effectiveness of XTORO in pediatric patients below 1 year of age have not been established.
See Full Prescribing Information
To learn more, visit XTORO.us